中國龍工(03339.HK)擬認購5億元基金
格隆匯10月28日丨中國龍工(03339.HK)公佈,於2019年10月28日,公司全資附屬龍工(福建)機械有限公司作為認購人與普通合夥人深圳高瓴天成三期投資有限公司就認購事項訂立該等協議。認購人將作為有限合夥人認購本金額人民幣5億元的深圳高瓴坤祺股權投資基金合夥企業(有限合夥)基金。
基金連同其平行投資載體深圳高瓴慕祺股權投資基金合夥企業(有限合夥)合計的目標募集規模不超過人民幣200億元。基金的主要投資範圍須為戰略新興產業中具有增長前景的企業或項目(不論處於成長或成熟階段),以及對注重通過科技賦能實現傳統企業增值的項目的長期股本投資。基金與其平行投資載體對投資項目進行共同投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.